Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Other Non-Current Liabilities: 2019-2021

Historic Other Non-Current Liabilities for Nurix Therapeutics (NRIX) over the last 1 years, with Aug 2021 value amounting to $796,000.

  • Nurix Therapeutics' Other Non-Current Liabilities fell 8.29% to $796,000 in Q3 2021 from the same period last year, while for Aug 2021 it was $796,000, marking a year-over-year decrease of 8.29%. This contributed to the annual value of $850,000 for FY2020, which is 51.07% down from last year.
  • Per Nurix Therapeutics' latest filing, its Other Non-Current Liabilities stood at $796,000 for Q3 2021, which was down 4.90% from $837,000 recorded in Q2 2021.
  • In the past 5 years, Nurix Therapeutics' Other Non-Current Liabilities registered a high of $1.7 million during Q4 2019, and its lowest value of $796,000 during Q3 2021.
  • For the 3-year period, Nurix Therapeutics' Other Non-Current Liabilities averaged around $986,667, with its median value being $843,500 (2020).
  • Data for Nurix Therapeutics' Other Non-Current Liabilities shows a maximum YoY plummeted of 51.07% (in 2020) over the last 5 years.
  • Over the past 3 years, Nurix Therapeutics' Other Non-Current Liabilities (Quarterly) stood at $1.7 million in 2019, then plummeted by 51.07% to $850,000 in 2020, then declined by 8.29% to $796,000 in 2021.
  • Its Other Non-Current Liabilities was $796,000 in Q3 2021, compared to $837,000 in Q2 2021 and $832,000 in Q1 2021.